FCA EGM Approves Separation of Ferrari
LONDON, December 3, 2015 /PRNewswire/ --
Fiat Chrysler Automobiles N.V. (NYSE: FCAU / MI: FCA) announced today that the resolution proposed to shareholders at the Company's Extraordinary General Meeting of Shareholders ("EGM") held today in Amsterdam was passed.
The EGM approved a demerger pursuant to which FCA will transfer all of the shares held by it in Ferrari N.V. to FE Interim B.V., a newly-formed Dutch company, and FE Interim B.V. will issue shares to FCA's shareholders ("Demerger"). The Demerger is part of a series of transactions that will be carried out to separate FCA's ownership interest in Ferrari N.V. and distribute that ownership interest to holders of FCA shares and mandatory convertible securities. Those transactions are expected to be carried out in early January 2016.
Details of the resolutions submitted to the EGM are available on the Company's corporate website at http://www.fcagroup.com.
This press release contains forward-looking statements. These statements are based on the Group's current expectations and projections about future events and, by their nature, are subject to inherent risks and uncertainties. They relate to events and depend on circumstances that may or may not occur or exist in the future and, as such, undue reliance should not be placed on them. Actual results may differ materially from those expressed in such statements as a result of a variety of factors, including: volatility and deterioration of capital and financial markets, including possibility of new Eurozone sovereign debt crisis, changes in commodity prices, changes in general economic conditions, economic growth and other changes in business conditions, weather, floods, earthquakes or other natural disasters, changes in government regulation, production difficulties, including capacity and supply constraints, and many other risks and uncertainties, most of which are outside of the Group's control.
SOURCE Fiat Chrysler Automobiles
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific Markets
- Sapreme Therapeutics announces oral presentation of new preclinical data on lead Duchenne muscular dystrophy candidate SPM-2551 at OTS 2026
- OMODA 5 NEXT Makes European Debut, Bringing Avant-Garde Design and Comfort to a New LOHAS Lifestyle
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Chrysler LLCSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share